Clorox (CLX), What Is Behind The Fresh Attention?
Clorox (CLX) just rolled out Clorox Purell ProCare, a combined health and hygiene platform built around CloroxPro and recently acquired GOJO, while affirming its regular quarterly dividend at $1.25 per share.
Despite the product launch and dividend affirmation, Clorox’s 30-day share price return is down 13.59%, and the stock has fallen 20.27% year to date. The 1-year total shareholder return decline of 31.68% points to fading momentum rather than a recent setback.
Compare Clorox’s recent slump with other household and consumer staples stocks by scanning our hand picked list of 31 resilient stocks with low risk scores for potentially steadier portfolio anchors.
Clorox now pairs a fresh hygiene push with a steep share price slide, which puts you at a crossroads: lean into today’s weakness or wait for a different valuation setup to emerge next.
Most Popular Narrative: 20.2% Undervalued
The most followed narrative pegs Clorox’s fair value at $100.76 per share, compared with a last close of $80.41. This frames the recent share price slide against a higher long term earnings story built around health and hygiene.
The main thing that has to go right is that Clorox turns its larger health and hygiene platform, including GOJO and Clorox Healthcare, into sustained growth and profitability while managing persistent cost inflation and value seeking consumer behavior.
The current valuation implies investors are pricing Clorox as if margin pressure, muted category growth, and legal or governance overhangs will weigh more heavily on the share price than the potential upside from health and hygiene growth, ERP driven productivity, and GOJO accretion.
See why 44 investors see Clorox as 20% undervalued.
Result: Fair Value of $100.76 (UNDERVALUED)
Still, this Clorox narrative leans heavily on ERP productivity keeping up with rising input costs, while an 85% to 90% payout ratio limits flexibility if cash flow tightens.
Find out about the key risks to this Clorox narrative.
Next Steps
Mixed feelings about Clorox’s setup so far. If this mix of pressure and potential has your attention, move quickly, review the full data, and weigh both the 3 key rewards and 2 important warning signs
Looking for more investment ideas beyond Clorox?
If Clorox has you rethinking your watchlist, broaden your search with a few focused stock ideas that match different risk, income, and quality preferences.
- Target potential turnaround stories by reviewing 8 elite penny stocks with strong financials that already pair stronger financials with smaller market caps.
- Zero in on value opportunities using the 31 high quality undervalued stocks that blend quality fundamentals with compressed valuations.
- Strengthen your income stream by scanning the 7 dividend fortresses that combine higher yields with a focus on stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com